Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.
2.

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.

Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW.

Immunol Rev. 2002 Oct;188:136-46. Review.

PMID:
12445287
3.
4.
5.

Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.

Slingluff CL Jr, Colella TA, Thompson L, Graham DD, Skipper JC, Caldwell J, Brinckerhoff L, Kittlesen DJ, Deacon DH, Oei C, Harthun NL, Huczko EL, Hunt DF, Darrow TL, Engelhard VH.

Cancer Immunol Immunother. 2000 Mar;48(12):661-72.

PMID:
10752474
6.

Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.

Engelhard VH, Bullock TN, Colella TA, Mullins DW.

Cancer J. 2000 May;6 Suppl 3:S272-80. Review.

PMID:
10874498
7.

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.

Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH.

J Exp Med. 2000 Apr 3;191(7):1221-32.

8.
9.

Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol.

Luckey CJ, King GM, Marto JA, Venketeswaran S, Maier BF, Crotzer VL, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH.

J Immunol. 1998 Jul 1;161(1):112-21.

10.

Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.

Kittlesen DJ, Thompson LW, Gulden PH, Skipper JC, Colella TA, Shabanowitz J, Hunt DF, Engelhard VH, Slingluff CL Jr.

J Immunol. 1998 Mar 1;160(5):2099-106. Erratum in: J Immunol 1999 Mar 1;162(5):3106. Shabanowitz JA [corrected to Shabanowitz J].

Supplemental Content

Loading ...
Support Center